|
 |
| Ex Vivo Metrics™: How Drug Studies in Reanimated Human Organs Could Revitalize the Drug Development Process
An editorial by Gerald Curtis, PhD
Fallout from the catastrophic phase I clinical trial of TeGenero’s monoclonal antibody TGN1412 in March 2006,1 in which 6 volunteers suffered life-threatening “cytokine storms,” includes newly tightened regulations in the United Kingdom and renewed concern worldwide about first-in-human trials, particularly for compounds with novel targets or mechanisms of action.
Read
more - More
Editorials
|
 |
| DNA
Genotyping from human FFPE Samples |
|
In this feasibility study, Applied Biosystems demonstrates how the combined
use Recover All Total Nucleic |
|
Acid Isolation Kit and TaqMan SNP Genotyping
Assay can result in high quality, reproducible, and reliable genotyping
data.. Read
more |
|
 |
Millipore has
launched the CellCiphr Cytotoxicity Profiling Assay Kit
using human HepG2 cells. This assay panel detects
drug-induced hepatotoxicity and is expected to be used
early in the drug discovery process. read
more
Cartesian Gridspeed, Ltd. announced the
opening of its new sales, marketing and technical support
subsidiary, SLIM Search, Inc. in Mission Viejo,
California. SLIM
Search, Inc. is marketing
its SLIM Search genomic search tool to universities,
government research, and research and development
departments of biotechnology corporations and individual
contributors. read
more
The new Variant Reporter Software from Applied
Biosystems automates detection of variants and
streamlines data analysis process. The software uses
proprietary algorithms to identify genetic variations
based on standardized or user-defined parameters. Results
are presented for validation in a visual format that
allows researchers to simultaneously compare multiple
quality control metrics. More information and a free trial
version are available at:
read
more
More
Products
|
 |
| We invite your comments and feedback for this edition of Biomarker Breakthroughs. Email us at
maloryea@gmail.com |
| |
|
|
The explosion in biomarker research and applications has let to a plethora of tools, approaches, and strategic considerations in this field. This newsletter will feature case studies, new developments, interviews, product news, regulatory issues, and exclusive reports from CHI and other meetings. Readers will learn how particular technologies are best applied, what new tools are available, how experts view new scientific discoveries in this field, how biomarkers are most quickly and efficiently discovered and validated, and how companies are actually using biomarkers in mechanism of action studies through clinical trials, as well as the development of biomarkers as diagnostics and therapeutic products.
Editor-in-Chief, Malorye Allison
|
|
|
